$1.740
-0.058 (-3.33%)At close
PLYX Comparative Benchmarking
In the context of the broader market, PLYX competes directly with industry leaders such as RGP and WFCF. With a market capitalization of $86.74M, it holds a significant position in the sector. When comparing efficiency, PLYX's gross margin of N/A stands against RGP's 36.47% and WFCF's 40.58%. Such benchmarking helps identify whether Polaryx Therapeutics, Inc is trading at a premium or discount relative to its financial performance.
Polaryx Therapeutics, Inc Financial Performance
Polaryx has shown a consistent negative net income, with losses increasing to $2,544,000 in Q1 2026. The current ratio is strong at 13.53, indicating good short-term financial health despite ongoing losses.
Financials
Related articles
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.